Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …

Cell death can be executed through distinct subroutines. PANoptosis is a unique
inflammatory cell death modality involving the interactions between pyroptosis, apoptosis …

Importance Patients with relapsed small cell lung cancer (SCLC), a high replication stress
tumor, have poor prognoses and few therapeutic options. A phase 2 study showed antitumor …

PURPOSE To provide evidence-based recommendations to practicing clinicians on the
management of patients with small-cell lung cancer. METHODS An Expert Panel of medical …

Purpose The chemotherapeutic agent doxorubicin (DOX) is limited by its cardiotoxicity,
posing challenges in its application for non-small cell lung cancer (NSCLC). This study aims …

With the promise of a potentially single‐dose curative regimen, CAR‐T cell therapies have
brought a paradigm shift in the treatment and management of hematological malignancies …

Introduction Small-cell lung cancer (SCLC) accounts for 15% of lung cancers and has a
dismal prognosis due to early dissemination and acquired chemoresistance. The initial good …

Trabectedin (TRB) and Lurbinectedin (LUR) are alkaloid compounds originally isolated from
Ecteinascidia turbinata with proven antitumoral activity. Both molecules are structural …

Dying tumor cells release biological signals that exhibit antigenicity, activate cytotoxic T
lymphocytes, and induce immunogenic cell death (ICD), playing a key role in immune …